The Na ϩ /I Ϫ symporter (NIS) is the plasma membrane glycoprotein that mediates active I Ϫ transport in the thyroid and other tissues, such as salivary glands, stomach, lactating breast, and small intestine. In the thyroid, NISmediated I Ϫ uptake plays a key role as the first step in the biosynthesis of the thyroid hormones, of which iodine is an essential constituent. These hormones are crucial for the development of the central nervous system and the lungs in the fetus and the newborn and for intermediary metabolism at all ages. Since the cloning of NIS in 1996, NIS research has become a major field of inquiry, with considerable impact on many basic and translational areas. In this article, we review the most recent findings on NIS, I Ϫ homeostasis, and related topics and place them in historical context. Among many other issues, we discuss the current outlook on iodide deficiency disorders, the present stage of understanding of the structure/function properties of NIS, information gleaned from the characterization of I Ϫ transport deficiency-causing NIS mutations, insights derived from the newly reported crystal structures of prokaryotic transporters and 3-dimensional homology modeling, and the novel discovery that NIS transports different substrates with different stoichiometries. A review of NIS regulatory mechanisms is provided, including a newly discovered one involving a K ϩ channel that is required for NIS function in the thyroid. We also cover current and potential clinical applications of NIS, such as its central role in the treatment of thyroid cancer, its promising use as a reporter gene in imaging and diagnostic procedures, and the latest studies on NIS gene transfer aimed at extending radioiodide treatment to extrathyroidal cancers, including those involving specially engineered NIS molecules. (Endocrine Reviews 35: 106 -149, 2014)
I. Introduction
T he significance of the thyroid gland for human health is difficult to overstate, given the wide-ranging effects of the thyroid hormones (THs) on prenatal and early development as well as on intermediary metabolism at all stages of life. Thyroid function, in turn, depends on an adequate supply of iodide (I Ϫ ), an essential constituent of the THs. I Ϫ reaches the thyroid via a highly specialized I Ϫ -concentrating system, the Na ϩ /I Ϫ symporter (NIS), the key plasma membrane transport protein located on the basolateral surface of thyrocytes. The thyroid's ability to concentrate I Ϫ was first identified in 1896 by Baumann (1, 2) . Fifty years later, in 1946, this ability of the thyroid began to be successfully exploited for the treatment of thyroid disease, including thyroid cancer (3) . Another 50 years passed before the molecule involved, NIS, was finally cloned in 1996 (4, 5) . Since then, NIS research has become a field of inquiry in its own right. Discoveries in this field have had a remarkable impact on numerous basic and translational areas, ranging from thyroid pathophysiology to the structure/function properties of other plasma membrane transporters, as well as on gene transfer, breast cancer, and even public health and environmental pollutants, to name but a few. The characterization of NIS has reached a particularly exciting point in the last few years, partly as a result of the recent elucidation of the crystal structures of bacterial analogs of various Na ϩ -driven transporters. In this article, we discuss the latest research on NIS and related fields, showing clearly that the more mechanistic information we obtain on NIS, the better equipped we are to identify, implement, and extend clinical applications for this remarkable molecule.
II. A Historical Perspective on I
؊ Deficiency I Ϫ deficiency (ID) and goiter, its most visible manifestation, have been observed throughout human history. Although goiter had already been described in ancient times as an "enlargement of the cervical gland" (Hippocrates, fifth century BCE), and besides descriptions just of "guttur tumidum" by the medical scholars of the Scuola di Salerno, goiter was first recognized as an enlargement of the thyroid gland by Albrecht von Haller in the 18th century (6) . Mountainous regions and areas far away from the sea have traditionally been plagued by endemic goiter and cretinism, both direct consequences of ID. Switzerland was one of the areas most afflicted by cretinism, and I Ϫ supplementation for humans and cattle was introduced in that country as early as 1922 (7) . This was the first mass nutritional intervention ever recorded. Pockets of endemic ID were also present in the United States, in the Great Lakes area and Northwestern states.
Evidence of a direct link between ID and cretinism came as late as 1966, from a controlled trial carried out in Papua New Guinea, in which half the families received injections of iodized oil and half received injections of saline (8) , dramatically reducing the incidence of cretinism and goiter in the treated group as compared with the control group, and only when I Ϫ supplementation was provided before the onset of pregnancy.
A. I ؊ is an essential micronutrient and its lack causes ID disorders
Inadequate dietary I Ϫ intake results in hypothyroidism and goiter at all ages. Mild ID also has a significant impact on reproductive health, increasing miscarriages and stillbirths, and is the most common cause of reproductive failure worldwide (9) . In addition, it is associated with increased perinatal mortality in the population (9, 10) . Insufficient I Ϫ intake in critical windows of development during fetal life and childhood results in the most dramatic manifestation of ID disorders (IDDs), ie, neurological cretinism, characterized by severe and permanent growth and cognitive impairment. The TH T 4 , which in-cludes 4 iodine atoms in its structure ( Figure 1 and Section III.B.), has a profound effect on brain development; it is required for myelination, somatogenesis, neuronal differentiation, and formation of neural processes, and its function is critical for proper development of the cerebral cortex, cochlea, and basal ganglia during the first trimester of gestation and for brain growth and differentiation in the third trimester (9) . IDDs form a spectrum and can result in wide variability in the severity of physical and cognitive symptoms. More subtly, suboptimal I Ϫ intake is a cause of reduced mental ability, lower school and work performance, and loss of an estimated 13.5 intelligence quotient (IQ) points at a population level (11) and intellectual potential (for a brief overview, see Refs. [11] [12] [13] . The urinary I Ϫ (UI) concentration (normal value Ͼ100 g/L) is a significant indicator of thyroid function and the most useful measure of I Ϫ status of a given population. Even in I Ϫ -sufficient countries, suboptimal I Ϫ intake still affects a significant number of people. In the United States, ϳ8% of the population has a UI Ͻ50 g/L. This percentage increases in women of reproductive age to 14.8%, and ϳ11% of pregnant women have also been reported to have a UI Ͻ50 g/L, both numbers higher than in previous years (14, 15) . Strikingly, ID is still the most common cause of preventable brain damage after starvation.
Resolutions were passed by international organizations, such as the United Nations, the World Health Organization (WHO), the United Nations Children's Fund (UNICEF), and the Food and Agriculture Organization (FAO), with the aim of eradicating IDDs by 2000, a goal that was later delayed to 2005. As a result of these efforts, currently 68% of the world's households have access to iodized salt, compared with 20% in 1990, and since 2003, . NIS (red circle), located on the basolateral surface of the thyrocyte, mediates Na ϩ /I Ϫ symport with a 2:1 stoichiometry. The driving force for this process is the Na ϩ electrochemical gradient generated by the basolateral Na ϩ /K ϩ ATPase (brown triangle). I Ϫ crosses the apical membrane via an unidentified carrier or carriers (purple structure with question mark) and is then oxidized and incorporated into Tg (green wire in the colloid) via an enzymatic oxidation carried out by TPO (pink), with the H 2 O 2 generated by Duox2 (also pink). Duox2A, an endoplasmic reticulum chaperone required for Duox2 maturation and function, is represented as a blue structure in the endoplasmic reticulum. Iodinated Tg is endocytosed and proteolyzed in the endocytic/lysosomal compartment (green intracellular vesicles), and THs are released into the bloodstream. I Ϫ incorporated into MIT and DIT is recycled through a deiodination reaction by the iodotyrosine dehalogenase Dehal1.
ClC-5, a H
ϩ /Cl Ϫ antiporter with a high permeability to I Ϫ (ϳ70% that of Cl Ϫ ) (35) , was found to be important for pendrin expression; in ClC-5 KO mice, which develop a euthyroid goiter, pendrin mRNA and protein expression are reduced by 60% (36) . However, the role of ClC-5 itself in thyroid I Ϫ efflux awaits further investigation.
The Na ϩ /monocarboxylate transporter (SMCT), a protein formerly known as AIT (for apical I Ϫ transporter), was cloned by using degenerate primers based on the NIS sequence and was thought to be the apical I Ϫ transporter owing to its striking homology with NIS (46% identity and 70% similarity) and its apical localization in thyroid cells (37) . However, it was later shown that SMCT does not transport I Ϫ ; instead, it transports a variety of monocarboxylates, including lactate, pyruvate, butyrate, and nicotinate, which is its most specific substrate (38) . The function of SMCT and its physiological substrates in the thyroid remain unknown. Interestingly, aside from its presence in the thyroid, the promoter of SMCT is hypermethylated in colon cancer (39) , and a correlation between SMCT expression in human colon cancer and patient survival has been shown (40) . The most relevant phenotype of the SMCT KO mouse is lactaturia. Intestinal cancer incidence was not increased in these animals, even when they were challenged with oncogenic chemicals or crossed with transgenic mice with mutant Secondary structure of NIS. The secondary structure model for NIS was constructed on the basis of biochemical data and the protein's structural homology with transporters whose 3-dimensional structures are known (for details, see Section VI). NIS is a 13-TMS protein, with the amino terminus facing the extracellular milieu and an intracellular carboxy terminus. TMSs I and XIII, and the loops between TMSs I and II and XII and XIII, are represented by dotted lines; their position relative to the other TMSs in the secondary structure could not be defined by homology modeling. Ten helical TMSs form an internal inverted topology repeat consisting of 5 transmembrane helical bundles (repeat 1, comprising TMSs II-VI, and repeat 2, comprising TMSs VII-XI), related to each other by a 2-fold pseudosymmetry axis running parallel to the membrane plane through the center. There are 3 glycomoieties (black trees), 1 between TMSs VI and VII and 2 between TMSs XII and XIII. Based on the crystal structures of several prokaryotic transporters (134 -136, 178) , unwound regions in the helices are predicted to provide flexibility and expose sideand main-chain contacts critical for substrate coordination. TMSs II and VII are proposed to define the substrate cavity accommodating both the anion and Na1, and TMS IX contributes to coordination of Na2 (as discussed in Sections VI.D. and VI.B. respectively).
tumor suppressors such as adenomatous polyposis coli (APC min ) (41) . In conclusion, although various candidate proteins that may mediate I Ϫ translocation across the apical membrane of thyrocytes have been proposed, at the present time, the identity of the I Ϫ apical translocation pathway remains poorly understood.
B. The complex machinery responsible for I ؊ organification
After its translocation into the follicular lumen, I Ϫ is first oxidized to iodine (I 2 ) and then covalently incorporated into tyrosyl residues on Tg. Iodinated tyrosyl residues are coupled on Tg to form THs, which are stored in the colloid covalently linked to the Tg backbone ( Figure  1 ). This 3-step process is catalyzed by thyroperoxidase (TPO), an apical monotopic membrane protein with a heme catalytic domain, which shares 44% similarity with leukocyte myeloperoxidase and faces the follicular lumen.
Iodine is covalently bound on 3 or 4 positions of tyrosyl residues on Tg. 3-Mono-iodotyrosine (MIT) and 3,5-diiodotyrosine (DIT), the iodinated TH intermediates bound to Tg, are then coupled by TPO via an ether bond to form T 3 and T 4 . After the iodophenol moiety of the Tg donor site is bound on the tyrosyl residue of the acceptor site, a dehydroalanine remains in the Tg backbone and quickly reacts with H 2 O to yield a serine (42, 43) . The oxidative power for I Ϫ organification is provided by H 2 O 2 generated by dual oxidase 2 (Duox2), a multispanning membrane protein belonging to the family of the nicotinamide adenine dinucleotide phosphate-dependent flavin adenine dinucleotide oxidases. The name dual oxidase stems from the presence of a lumen-facing domain that exhibits Ͼ45% amino acid similarity with TPO, with putative and controversial peroxidase activity (44 -46) . Interestingly, Duox2 shares 47% amino acid similarity to gp91 phox (Nox2), which is responsible for the respiratory burst and the production of reactive oxygen species (ROS) in neutrophils (45) . In contrast to most of the proteins involved in TH biosynthesis, Duox2 expression and activity do not appear to be regulated by TSH (47) (48) (49) . On the other hand, Duox2 activity is enhanced by a rise in the intracellular Ca 2ϩ concentration. Mutations in DUOX2 and in DUOXA2, its maturation factor and chaperone, have been identified as causes of congenital hypothyroidism (CH) (50, 51) . Because in some cases transient hypothyroidism occurs (TH biosynthesis is restored to a level where pharmacological supplementation is no longer needed, usually during late childhood or adolescence) (52) , it was postulated that permanent hypothyroidism was caused by biallelic DUOX2 mutations and transient hypothyroidism by heterozygous mutations. However, recent evidence suggests that other mechanisms are in place, as transient hypothyroidism has also been observed in patients with homozygous mutations (briefly summarized in Ref. 53) . Because H 2 O 2 generation is absolutely required for TH biosynthesis, it is possible that Duox1, which is functionally identical to Duox2 but has a different tissue distribution pattern and regulation, is upregulated to compensate for the loss of Duox2.
Tg is a highly glycosylated 660-kDa homodimer with 132 Tyr residues. Strikingly, each Tg molecule contains on average only 5 MIT, 5 DIT, 2.5 T 4 , and 0.7 T 3 moieties, distributed on only one-third of all Tyr residues, with some hormonogenic positions that are preferentially iodinated (43) . Iodinated Tg is stored in the follicular lumen in a colloidal form, including insoluble microglobules of protein, highly cross-linked with disulfide, dityrosine, and glutamyl-lysine bonds (27) . Tg is internalized via endocytosis or micropinocytosis under basal conditions. When TSH serum levels increase, all steps of TH biosynthesis and release are stimulated, including Tg internalization. Pseudopod formation and Tg macropinocytosis occur within minutes of TSH stimulation; internalized Tg undergoes proteolytic cleavage in lysosomes, and T 3 and T 4 are then released into the bloodstream (43) . In this process, MIT and DIT from partial or incomplete TH synthesis are also released. Interestingly, it was discovered over 50 years ago that MIT and DIT produced during Tg proteolysis, and accounting for 70% of Tg iodine content, are metabolized in the thyroid to I Ϫ and Tyr by a nicotinamide adenine dinucleotide phosphate-dependent flavin mononucleotide (FMN) iodotyrosine dehydrogenase (Dehal1) (52, 54 -56) . The Dehal1 gene (IYD) and its CH-causing mutations were identified only recently (57 Figure 3A ). Putative ortholog proteins for TH biosynthesis (TPO and Tg), a putative TH receptor, and thyroid development proteins (thyroid transcription factor-1 Foxe-1 and Pax8) have all been identified in the endostyle, a specific organ used for feeding, in the most basal, nonvertebrate chordates, namely urochordates (such as Ciona intestinalis) and cephalochordates (eg, amphioxus) (60, 61) . In the parasitic lamprey, a basal vertebrate, a thyroid-like structure with a follicular organization develops after metamorphosis in addition to the endostyle (62) .
Although they lack a thyroid-like organ, invertebrate development is also affected by THs ( Figure 3B ). In echi- . Evolution of THs: from unicellular algae to mammals. A, In the phylum Chordata, TH biosynthesis is required to signal for metamorphosis (in Protochordata and amphibians) and for development and homeostasis (in vertebrates). In the subphylum Protochordata, which includes Tunicata and Amphioxus, THs are produced in the endostyle, an exocrine gland associated with the pharynx and used for feeding, and end up in the esophagus together with food. In the parasitic lamprey, the endostyle is present during the larval stage, but after metamorphosis, it is replaced by a thyroid. Control of thyroid function by TSH has never been demonstrated in jawless fish, and pituitary modulation of TH synthesis is a characteristic of higher vertebrates. B, Unicellular algae, which use I Ϫ /I 2 as an antioxidant system, synthesize iodothyronines from marine components. Echinoid larvae feeding on phytoplankton (green box) evolved to sense algal T 4 as a cue to the amount of energy available for their development, in a process called cross-kingdom cross-talk. Lecithotrophic larvae, which evolved from echinoids with planktotrophic larvae (purple box), are not exposed to environmental iodothyronines; however, TH signaling became essential for their metamorphosis earlier in evolution, and rather than losing THs as a development-inducing signal, these larvae evolved the ability to synthesize their own iodothyronines. Facultative feeding larvae (blue box) acquire T 4 from the plankton they feed on but also synthesize endogenous T 4 , which in some cases can be enough to trigger metamorphosis in the absence of food. In larvae that depend on food to undergo metamorphosis, exogenous administration of T 4 rescues the effect of food withdrawal (ie, inhibition of metamorphosis), whereas the TH synthesis inhibitor thiourea does not, demonstrating that T 4 is both necessary and sufficient for metamorphosis and indicating that endogenous TH biosynthesis does not occur in these organisms. In contrast, thiourea inhibits metamorphosis in nonfeeding larvae, and these larvae also incorporate 125 I Ϫ into THs. This indicates that endogenous TH biosynthesis occurs in nonfeeding larvae and that it triggers a developmental step in these organisms.
noids (sea urchins, sea biscuits, sand dollars, and sea cucumbers), larval and juvenile morphogenesis, as well as metamorphosis, are influenced by exogenous T 4 . Echinoderms can develop from nonfeeding larvae, feeding larvae, or nonobligatorily feeding larvae. Intriguingly, exogenous T 4 produces the same effects in feeding larvae as exposure to algae (ie, to a food-rich environment), in contrast to the morphologic effects of a low-food environment (development of larval structures instead of juvenile structures and delay in reaching metamorphosis) ( Figure 3B, left) . The remarkable similarity of the effect of T 4 to that of food abundance suggests that the developmental cue in food that echinoid larvae respond to is actually T 4 . Interestingly, larvae that develop without feeding (63) , and therefore cannot acquire algal T 4 , have been found to synthesize T 4 ( Figure 3B , right) via a mechanism sensitive to thiourea (a TPO inhibitor). In nonfeeding larvae, exposure to thiourea favors the development of larval structures at the expense of juvenile structures and also delays the acquisition of metamorphic competence. In addition, exposure to T 4 favors the development of juvenile structures in a dose-dependent manner and can rescue the developmental effects of thiourea-treated larvae ( Figure 3B , right). The prediction was that facultative feeding larvae were more dependent on endogenous T 4 biosynthesis than feeding larvae ( Figure 3B , middle). This was confirmed in 2 sea biscuit larvae, Dendraster excentricus (which develops from an obligatorily feeding larva) and Clypeaster rosaceus (which develops from a facultative planktotrophic larva) (64, 65) . The latter can also synthesize endogenous T 4 in a thiourea-dependent fashion, but not enough to trigger metamorphosis in the absence of food. An example of the dramatic developmental dependence of these organisms on T 4 is that, in a sand dollar (Leodia sexiesperforata), the availability of exogenous T 4 induces a switch in developmental mode from obligatorily feeding to facultative feeding larvae, which can undergo complete metamorphosis in the absence of food (65) .
Why did invertebrates evolve a TH-dependent plasticity pathway? The hypothesis is that phytoplankton is a source of hormone or prehormone to echinoderm larvae via the food chain (trophic interaction) (66) . T 4 , and T 3 in smaller amounts, has been found so far in 3 unicellular algae (Dunaliella tertiolecta, Isochrysis aff. Galbana, and Rhodomonas lens) (67) and a diatom (Chaetoceras gracilis) (68) . Notably, T 4 is one order of magnitude more potent than T 3 in feeding sea urchin larvae (68) . The building blocks of TH are all present in the marine environment as follows (67) : iodine species that are found in seawater at a concentration of 0.5M, mainly in the form of iodate (IO 3 Ϫ ) and I
Ϫ
; micro-and macroalgae that can contain up to 1% iodine in organic or inorganic forms; and tyrosine that can be either transferred from symbiotic algae or acquired from the water-dissolved organic matter. It is possible that algal biosynthesis of iodotyrosines via haloperoxidases evolved as a detoxification reaction to protect against ROS (69) . Organisms feeding on algae later evolved a system to detect iodotyrosines as an energy-related plasticity cue, in an evolutionary mechanism called cross-kingdom cross-talk (62, 66, 67) (Figure 3B) . A classic and well-studied example of this phenomenon is the interaction between plants and arthropods. All arthropods lack sterol synthesis, but the synthesis of ecdysteroids (arthropod hormones) requires sterols, which arthropods obtain via trophic interactions with autotrophs. The hypothesis is that autotrophs evolved to produce compounds (for example, phytosterols) to deter excessive predation, and arthropods coevolved to tolerate high concentrations of these compounds by metabolizing them and eventually evolved to use them as developmental signals (66) .
Iodotyrosine signaling in invertebrates may have evolved from cross-reaction with nuclear receptors; however, the invertebrate TH receptor-like proteins that have been characterized so far do not show high affinity for TH or bind DNA. It is conceivable that, in invertebrates, THs act through a different mechanism, such as plasma membrane receptors. This phenomenon is also observed in the arthropod-plant coevolution; arthropod ecdysteroid hormones signal through a nuclear receptor, whereas plant gibberellins act via different plasma membrane mechanisms (66) .
The mechanism of I Ϫ transport in invertebrates is not known. In the nonfeeding sand dollar Peronella japonica, thiourea and ClO 4 Ϫ both delay metamorphosis (63 Figure 3B ), they evolved strategies to cope with a temporary shortage of I Ϫ supply, such as TSH regulation of TH synthesis, a follicular thyroid structure that allows THs to be stored ( Figure  3A ), mechanisms to recycle I Ϫ from the thyroid (iodotyrosine dehalogenases, such as Dehal1), and the body pool (peripheral deiodinases and NIS expression in salivary glands and stomach). It is also possible that a positive selection was in place to keep useful, non-TH-related roles of I Ϫ accumulation in the body, such as the antimicrobial role in the mucosal surface host defense system (72) (Section VII).
A. THs in human development
In mammals, the first glandular tissue to develop is the thyroid gland. The thyroid begins to take up I Ϫ and secrete
THs as early as 10 to 12 weeks of gestation in humans (73) . Before this, maternal TH is critical for fetal development and is provided via placental vessels. Thyroid follicular cells arise from the embryonic endoderm. The anlagen, a thickening in the floor of the primitive pharynx between the first and second brachial arches, becomes apparent at gestational day 17. The anlagen proliferates ventrally and laterally to form the characteristic bilobed structure of the thyroid gland (43) . In humans, thyroid morphogenesis is completed by gestation week 7, when the gland descends to its permanent pretracheal position. At this point, thyrocyte precursors are still undifferentiated but begin to express thyroid-specific and thyroid-related genes (TSH receptor [TSHR] and DUOX2 followed by TG, TPO, and pendrin [SLC26A4]) (74) . NIS expression is the limiting step in the terminal differentiation and onset of thyroid function, being the last to appear at gestation week 10, just before the beginning of hormonogenesis. At this stage, although the NIS protein is mainly found in perinuclear compartments, basolateral localization is observed in very few thyrocytes, but it is enough to initiate fetal I Ϫ accumulation (74) . The thyroid gland is considered terminally differentiated at gestation week 11, once thyrocytes have fully polarized, formed follicles, and fetal TH synthesis begins (74) . THs play a critical role in the development of the CNS of the fetus and newborn, affecting neuronal migration, differentiation, myelination, and synaptogenesis ( Figure  4A ) (75) (76) (77) (78) (79) (80) (81) . The importance of T 3 and T 4 in the CNS is underscored by the fact that at week 12 of gestation, both hormones can be detected in the cortex but not in other tissues or in serum (80) . TH insufficiency can cause severe neurodevelopmental defects, cretinism being the gravest. In fact, even a slight reduction in maternal T 4 production (hypothyroxenemia) during gestation can impair cognitive development in the newborn and result in decreased IQ (82, 83) . At birth, maternal T 4 accounts for 20% to 50% of the T 4 measured in cord blood ( Figure 4A ) (81, 84) . Interestingly, symptoms of CH in babies born to euthyroid mothers do not manifest at birth. On the other hand, insufficient maternal thyroid function may influence the thyroid status of the fetus, even after it gains the ability to produce its own THs, and so should be monitored closely (85) . Consistent with the increased demand for TH in pregnancy, human chorionic gonadotropin (CG) has been shown to increase I Ϫ transport and NIS expression in the highly functional rat thyroid-derived FRTL-5 cells in a dose-dependent manner (86 -88 (89, 90) . The contribution of maternal THs, the sensitivity of the fetus to THs, and consequently the absolute requirement for an adequate supply of I Ϫ during pregnancy have been a subject of debate. As late as 1971, the hypotheses concerning the effect of ID on fetal brain development were several: 1) that I Ϫ had an effect per se on brain function, 2) that fetal hypothyroidism had the most relevant impact, and 3) that maternal hypothyroidism had the most relevant impact (91) . The importance of maternal thyroid health was first recognized at the beginning of the 20th century by physicians aware of severe endemic goiter and cretinism in regions such as the Swiss Alps and the Himalayas (10, 92) . Studies performed in the 1960s found that women in areas where ID was common had low levels of serum proteinbound I Ϫ (a measure of T 4 ), which physiologically increases at the onset of pregnancy (93) . The maternal T 4 surge is mainly caused by the high circulating levels of CG produced by the embryo. CG, a glycopeptide hormone of the same family as TSH, cross-reacts with the TSH receptor and causes an increase in TH synthesis, to such an extent that maternal TSH is generally suppressed. This is a mechanism by which embryos ensure that they receive enough THs independently of the maternal thyroid status (94) . It also became evident that elimination of neurological cretinism, characterized by a deaf-mutism and neuromuscular impairment phenotype, required a preventive intervention by correcting ID in the prenatal period, mainly in the first 2 trimesters of pregnancy, corroborating the observation that maternal THs are needed for the child's CNS development. However, in the second half of the 20th century, these findings were disregarded, and the view that maternal T 4 transfer was blocked by the placental barrier and the child becomes sensitive to T 4 only after birth became predominant. The confusion was generated by the observation that athyroid newborns affected by CH could be effectively treated by prompt administration of T 4 , suggesting that the fetus is insensitive to THs until after birth, and that neurological cretinism is not observed in children from hypothyroid mothers, reinforcing the hypothesis that maternal THs are not important for fetal growth ( Figure 4B ). The confusion was further exacerbated by the fact that the general living condition improvements in many regions had decreased the incidence of cretinism without I Ϫ supplementation (95) .
Questions about the physiological significance and role of T 4 in fetal development arose also from the finding that T 4 levels in fetal blood are extremely low (100-fold lower than in maternal serum). Studies by Morreale de Escobar and colleagues (92, 96, 97) revealed that, although the fetal serum T 4 concentration is lower than the maternal one, when the proportion of free T 4 (ie, the active form not bound to serum transport proteins) is taken into account, fetal T 4 levels are comparable to adult ones. T 3 increases in the fetal cerebral cortex steadily with gestation to levels comparable to those in adults (2.5 pmol/g), due to local type-2 deiodinase activity, whereas T 3 concentration in the fetal serum remains constant and low. THs are found in embryonic and fetal tissues before the onset of fetal thyroid function (96) , and they correlate with maternal hormone concentrations until the fetal thyroid starts functioning and actually secreting THs after maturation of the pituitary portal Figure 4 . THs in human development and effects of ID and maternal hypothyroidism on fetal development. A, Maternal dietary I Ϫ and T 4 are critical over the entire course of gestation. The fetus's thyroid starts producing THs at ϳ20 weeks, but the mother's T 4 contribution is still crucial. After birth, maternal I Ϫ , which is transferred by NIS into the milk, is key for the newborn's development. Light blue arrows indicate the time of development of specific brain areas and body features that depend on adequate T 4 levels and can be affected by low T 4 at the indicated time of gestation. Neurological or myxedematous cretinism features occur depending on the onset and levels of maternal hypothyroxinemia or hypothyroidism. Congenital hypothyroidism due to fetal mutations in TH synthesis genes have a negative impact after birth, when the supply of maternal T 4 is interrupted. B, Effects of maternal thyroid conditions on fetal development and preventive measures. system (92, 97) . Rather than demonstrating that the fetus is insensitive to T 4 until after birth, the phenotype of athyroid children, who are born healthy and develop myxedematous cretinism (a less severe form of growth and mental impairment than neurological cretinism) after birth (91) , shows that the maternal input of THs remains significant also after fetal TH is found in cord blood (84, 98) . It is widely accepted that maternal subclinical hypothyroidism, defined by mild TSH increase associated with normal TH values ( Figure 5A ), needs immediate correction. However, it is often overlooked that maternal free T 4 should also be closely monitored and that maternal hypothyroxinemia, without changes in TSH levels ( Figure 5B ), negatively affects progeny neurodevelopmental markers ( Figure 4B ). Of note, ID is the most common cause of maternal hypothyroxinemia (98, 99) . The relationship between psychomotor impairment (100) at 10 months of age (101) and other developmental indices at 3 weeks, 1 year, and 2 years of age correlates with maternal free T 4 in the first trimester (102) and not with maternal TSH serum concentration (reviewed in Ref. 10 ). In fact, increased serum TSH is seldom found in ID, and when it occurs, it is much less pronounced in I Ϫ -deficient subjects than in patients with a similar decrease in T 4 /T 3 levels arising from other conditions (103) (104) (105) . These important differences in ID, as compared with hypothyroidism due to illness, result from a thyroid autoregulatory system working in ID that has not been characterized at the molecular level. Immediate effects of thyroid autoregulation in response to ID include increased T 3 over T 4 synthesis (106 -108); increased thyroid vascularization, blood flow, and volume; hyperplasia; increased acinar cell height; and increased I Ϫ uptake (97) . All these changes occur well before and independently of changes in TSH, as they were also shown to take place in hypophysectomized animals (109, 110) . As a result, serum T 3 is not significantly altered, and paradoxically, the body maintains a euthyroid state with low TSH and adequate T 3 levels. Thus, TSH screenings are insufficient predictors in ID populations. However, some tissues, such as brain (111), which rely almost exclusively on local T 3 synthesis by the action of type-2 deiodinase, which converts circulating T 4 to T 3 , may be selectively hypothyroid, because lower circulating levels of T 4 preclude reaching normal tissue T 3 concentrations. This phenomenon also occurs in fetal brain, as elegantly demonstrated by Morreale de Escobar and collaborators (326) . Dams treated with an organification blocker (to prevent endogenous TH synthesis) were given T 4 or T 3 , and the concentration of the hormones was measured in maternal and fetal blood and tissues. Surprisingly, administration of enough T 3 to dams to normalize maternal and fetal serum T 3 levels failed to increase the T 3 concentration in fetal brain. In contrast, T 4 administration rescued fetal brain T 3 to normal values (92, 96) . The lack of distinction between ID-and CH-induced neurological disorders ( Figure 4B ) had 2 important neg- ative consequences: 1) it was overlooked for a long time that patients with ID needed I Ϫ supplementation as a preventive measure (unlike those with some kinds of CH due to genetic mutations in the fetus, which can be treated after birth with prompt administration of T 4 ); and 2) pregnant women were screened for TSH, but not T 4 . Although TSH levels are extremely effective in identifying CH due to subclinical maternal hypothyroidism, they are not optimal for detecting ID, as discussed above (92).
V. NIS, the Mediator of Active I
؊ Uptake in the Thyroid and Beyond
A. Molecular identification of NIS
The rat NIS (rNIS) cDNA was cloned in our laboratory by functional expression in Xenopus laevis oocytes from a highly functional rat thyroid cell line (FRTL-5 cells) (5). Our group has since extensively characterized the protein (5, 24, (112) (113) (114) (115) (116) (117) (118) and generated high-affinity site-directed antibodies (113) . NIS relies on the Na ϩ electrochemical gradient, maintained by the Na ϩ /K ϩ ATPase, to drive the transport of the second anion substrate (for example I Ϫ )
into the cell. By coupling the inward transport of Na (122) . The experimentally tested secondary structure model of NIS depicts a hydrophobic protein of 618 amino acids with 13 transmembrane segments (TMSs), an extracellularly facing amino terminus, and an intracellular carboxy terminus (114) (Figure 2 ). NIS is a phosphoprotein, and most phosphorylation occurs on its carboxy terminus. The carboxy terminus is also important for NIS trafficking and its localization at the basolateral plasma membrane (123) . NIS is a highly glycosylated protein (114) , with 3 N-linked glycosylation sites (1 in the loop between TMS VI and VII and 2 in the loop between TMS XII and XIII) ( Figure 2) ; however, glycosylation is not essential for function, as demonstrated by the high activity and the same K m for I Ϫ displayed by an NIS mutant protein in which all 3 glycosylated Asn were replaced with Gln (114) .
Given the highly significant roles that NIS plays in physiology and medicine, it is imperative that we uncover the protein's substrate translocation pathways. There is novel evidence, derived from the detailed characterization of positions where NIS mutations have been found in patients and from structural homology modeling (see Section VI), that TMS III, VII, and IX are key for substrate coordination, coupling, stoichiometry, and translocation ( Figure 2 ).
Using primers derived from the rNIS sequence, the human NIS (hNIS) cDNA was cloned by Jhiang's group (124) . hNIS shares 84% amino acid identity and 93% similarity to rNIS. The major differences between the 2 proteins are a 5-amino-acid insertion between the last 2 TMSs and a 2-amino-acid insertion at the carboxy terminus (amino acids 618 -637) of hNIS. The hNIS gene is located on chromosome 19p12-13.2 and encodes an integral membrane glycoprotein of 643 amino acids. NIS belongs to solute carrier family 5 (gene name SLC5A5); other Na ϩ -dependent transporters, which share high sequence homology with NIS, belong to the same family, including the Na ϩ /glucose transporters (SGLT-1 and 2), the Na ϩ /monocarboxylate transporters (SMCT-1 and -2), the Na ϩ /multivitamin transporter (SMVT), and the Na ϩ / myoinositol transporter (SMIT) (125) .
B. NIS substrates

Anions
In addition to its well-known I Ϫ transport activity, NIS mediates the translocation of other anions (112), according to the following order of maximal transport rates: Tc is widely used in nuclear medicine, because its decay emission energy (140-keV ␥-rays) and its short (6 hours) half-life make it extremely useful for imaging and diagnostic procedures.
Two other compounds, perrhenate (ReO 4 Ϫ ), which is available as 188 ReO 4 Ϫ and has a potentially attractive clinical use in the treatment of tumors expressing NIS endogenously or via gene transfer (Section IX.E.), and ClO 4 Ϫ , a competitive NIS inhibitor and environmental pollutant, are also NIS substrates (126 -129) and will be discussed in more detail below (Section V.C.).
Cations
The Na ϩ specificity of Na ϩ -dependent transporters is not absolute. In some instances, transport can be driven by cations other than Na (129) Additional studies by 2 other groups support these results. One group used a halide-sensitive yellow fluorescent protein (149) , and the other relied on ion chromatography coupled to tandem mass spectrometry (150 -152) on the health of adult women, if a nursing mother is exposed to high levels of ClO 4 Ϫ , the anion will not only inhibit I Ϫ accumulation in the milk, which is critical for TH biosynthesis by the newborn, but also will itself be actively concentrated in the milk and thus directly inhibit the newborn's thyroidal I Ϫ uptake. This effect would have potentially serious consequences for the child's mental and physical development.
VI. Recent Advances in Structure/Function of NIS
Major strides in the elucidation of structure/function attributes of NIS have been made in recent years. A par- . In vitro and in vivo bioassays reveal that perchlorate is a NIS substrate actively transported against its concentration gradient. A, A polarized monolayer of MDCK cells stably transfected with a NIS mutant that is targeted exclusively to the apical surface was exposed to ClO 4 Ϫ to allow for vectorial transepithelial transport. After a 2-hour incubation, an aliquot was taken from each compartment to assess its effect on 125 I Ϫ transport in NIS-expressing cells grown on a plastic dish. The degree of I Ϫ transport inhibition in cells reflects the amount of ClO 4 Ϫ present in the aliquot, and can be quantified by serial dilutions and by measuring the inhibition by ClO 4 Ϫ of I Ϫ transport in kinetic experiments (129) . B, ClO 4 Ϫ is actively concentrated in maternal milk. To assess whether NIS transports ClO 4 Ϫ into maternal milk in vivo, lactating dams were injected ip with ClO 4 Ϫ or saline solution. Pups were separated from their mothers, and lactation was stimulated with oxytocin. Milk collected from the dams was diluted to investigate its effect on 125 I Ϫ transport in NIS-expressing cells grown on a plastic dish. The degree of inhibition of I Ϫ transport is directly correlated to the amount of ClO 4 Ϫ present in the sample, and ClO 4 Ϫ concentration can be quantified by serial dilutions and inhibition kinetics. Based on the distribution volume of ClO 4 Ϫ and its IC 50 , it was determined that ClO 4 Ϫ is actively concentrated in maternal milk (129) .
doi: 10.1210/er.2012-1036 edrv.endojournals.orgticularly rich source for this information has been the investigation of amino acid positions that have been found mutated in patients with CH due to an I Ϫ transport defect (ITD). Another key source of structure/function data has been the determination of the crystal structures of prokaryotic homologs of eukaryotic Na ϩ -driven transporters as well as homology models based on those structures.
A. CH-causing NIS mutations have been a rich source of structure/function information on NIS
As mentioned earlier, CH results in goiter and impaired physical and mental development when not recognized immediately after birth and left untreated. In CH due to fetal somatic mutations, maternal THs are transferred to the fetus via the placenta, allowing for proper fetal development. The newborn's TH insufficiency manifests itself after birth, when maternal T 4 transfer is interrupted and the newborn's CNS development relies entirely on its own TH biosynthesis. CH occurs in 1 in 2000 -4000 live births, and is diagnosed with routine newborn thyroid screening tests (73, 154) , which have been implemented for over 2 decades in most developed countries.
Thyroid gland developmental failure (thyroid dysgenesis) is caused by mutations in transcription factors, such as thyroid transcription factor-1, Pax-8, and NK2 homeobox 5 (NKX2.5) (encoded by the NKX2-1, PAX8, and NKX2-5 genes, respectively) (155) (156) (157) (158) (159) (28, 50, 57, 160 -162) . CH resulting from mutations in SLCA5A, the gene encoding NIS, is specifically referred to as ITD, because it is a direct result of a nonfunctional NIS molecule and therefore an inability of the thyroid to concentrate I Ϫ . ITD follows an autosomal recessive inheritance pattern and is diagnosed by reduced or absent thyroid I Ϫ uptake and a low saliva-to-plasma I Ϫ ratio (Ͼ20 in nonaffected subjects). When untreated, ITD is clinically characterized by hypothyroidism, goiter and mental impairment of varying degrees. Although ITD is a rare autosomal recessive disorder, to date, 13 such mutations have been reported in the NIS coding region (V59E [163] , G93R [164] , R124H [165] , ⌬143-323, Q267E [166] , C272X, ⌬287-288 [167] , T354P [133] , ⌬439 -443 [168] , G395R [164] , G543E [169] , 515X, and Y531X) ( Figure 7 ) and 1 in the 5Ј-untranslated region (Ϫ54 C3 T transition) (170) . In the absence of a crystal structure for NIS, valuable structure/function data on NIS have been obtained from the study of patients who bear mutations in the NIS gene. Molecular characterization of the mutations indicated in Table 1 has provided novel information on the molecular requirements for NIS function at specific amino acid po- . Experimentally tested NIS secondary structure model. Gray cylinders represent TMS; gray lines, extracellular segments; black lines, intracellular segments; and branches, N-linked glycosylation sites (N225, 485, and 497). NIS mutations identified in patients with ITD are indicated using the single-letter amino acid code. Those for which the letters are outlined in red (V59E, R124H, Q276E, T354P, G395R, G543E, and ⌬339 -443) have been studied at the molecular level, as has the effect of different amino acid substitutions at these positions. ⌬ indicates deletions, and X terminations. [172] , and SGLT mutations associated with glucose malabsorption [173] ) result in intracellular retention of these proteins. Mutations in NIS, however, do not impair NIS expression at the plasma membrane, for the most part (Table 2 ).
B. Identification of transmembrane segment IX amino acids key for Na ؉ binding and/or translocation
Notably, analysis of the T354P substitution, the first NIS mutant reported (174) , revealed that position 354 requires an OH group at the ␤-carbon (175) and led De la Vieja et al (133) to study other ␤-OH-containing residues in TMS IX. After substituting all the Ser and Thr in TMS IX, it was determined that 5 of these (S351, S353, T354, S356, and T357) are important for NIS function. When Ala, Cys, or Pro was substituted at these positions, activity was decreased or absent. I Ϫ transport requires an amino acid bearing a ␤-OH group at these positions. Furthermore, a reduced apparent affinity for Na ϩ was noted when the Na ϩ dependence of I Ϫ transport was examined, indicating that these amino acids are involved in Na ϩ binding/translocation. In 2005, the structure of LeuT, a bacterial homolog of neurotransmitter transporters, was determined at atomic resolution (134) . The LeuT structure was a milestone that greatly advanced the understanding of the structural basis for how eukaryotic Na ϩ -driven symporters belonging to different families work. Although NIS and LeuT belong to different families and bear no sequence similarity, De la Vieja et al (133) proposed the possible existence of structural homology between the two, based on evidence emerged from the study of an ITD-causing mutation identifying S353 and T354 in NIS TMS IX as critical for Na ϩ translocation. These NIS residues correspond to those in TMS VIII of LeuT (T354 and S355) shown to coordinate Na2 (133, 134) . Our prediction was confirmed a year later, when the structure of vSGLT, the Na ϩ /galactose transporter from V. parahaemolyticus, revealed the same fold as LeuT (135), even though there is very little sequence homology (Ͻ17%) between the 2 proteins. The relevance of the structure of vSGLT for NIS becomes readily apparent when one considers that the 32% identity and 60% similarity of the prokaryotic vSGLT to its own eukaryotic analog SGLT-1 are extremely close to the 27% identity and 57% similarity that exist between vSGLT and NIS, which after all belongs to the same SLC5 family as SGLT1 (135, 176, 177) . These considerations provided the basis for us to generate a homology model of NIS (Figure 8 ) based on the structure of vSGLT (71).
C. A crucial structure/function insight from the analysis of NIS mutants: seemingly unrelated transporters may exhibit a common fold and other shared characteristics
That proteins with unrelated sequences have a common structural fold is clear (177) . Within the last few years, 4 structures of bacterial Na ϩ -driven transporters sharing the same fold have been determined at atomic resolution by x-ray crystallography: LeuT; vSGLT (135), a homolog of the eukaryotic SGLT-1; the benzyl-hydantoin transporter (Mhp1) from Mycobacterium liquefaciens (136) , a member of the nucleobase cation symport-1 (NCS1) family of transporters; and the Na ϩ /betaine symporter (BetP)
from Corynebacterium glutamicum, a member of the betaine/choline/carnitine transporter (BCCT) family (178) . Since then, numerous structures of other Na ϩ -driven and H ϩ -driven transporters and even antiporters, with no homology to LeuT but exhibiting the LeuT fold have been reported (SGLT [135] , Mhp1 [136] , BetP [178] , ApcT [139] , AdiC [137, 138] , and CaiT antiporter [179] ). The conservation of the structural fold suggests the existence of an evolutionary relationship between them. Remarkably, although all 4 structures (LeuT, vSGLT, Mhp1, and BetP) belong to different gene families and lack sequence homology, they share common structural features: inverted topology repeats, unwound helices in regions critical for substrate binding, and a similar way of coordinating Na ϩ (134 -136, 178) . In all cases, 10 helical
TMSs containing an internal inverted topology repeat of 5 TM helical bundles are present; the first bundle (TMSs I-V) is related to the second one (TMSs VI-X) by a 2-fold pseudosymmetry axis running parallel to the membrane plane through the center. The high degree of structural homology between these internal repeats (root mean square deviation 3.8 -4.5 Å) allows superimpositition of these structures onto one another (176) . The helical bundles are arranged in such a way that TMS I, II, III, VI, VII, VIII, and X face the central pore where the substrates reside (176) . Given the diversity of substrates for these transporters, it is not unexpected that the specific interactions required to coordinate each substrate are unique. However, despite the variability of the specific interactions, the inverted repeat topology provides a general scaffold capable of accommodating a wide range of substrates. For instance, the substrate leucine in LeuT is coordinated directly by carbonyl groups of the main-chain atoms (TMSs I and VI). In vSGLT, the OH groups of galactose are coordinated by H-bonds from polar side chains from TMSs I, VI, VII, and X (135) . In Mhp1, benzyl-hydantoin resides between 2 tryptophan residues provided by TMSs III and VI and is coordinated by glutamine and asparagines from TMSs I Figure 8 . Figure 8 . NIS homology model. A, An NIS 3-dimensional homology model was generated by sequence and structural alignment with vSGLT (27% identity and 57% similarity). The homology model was built on manually corrected sequence alignment. The resulting model was then manually adjusted to improve side-chain interactions and energy minimized. The color code used for the TMSs is the same one used for the secondary structure model (inset, and Figure 2 ). Helices are represented by cylinders. The model is oriented with the extracellular and intracellular milieux on the top and bottom, respectively. The amino and carboxy termini, along with TMSs I and XIII, are not present in the reference 3-dimensional structures and therefore cannot be modeled. B, Helical model depicting the bundle (TMSs II-III from repeat 1 in red, and VII-VIII from repeat 2 in orange), and the scaffold (TMSs III-V from repeat 1 in blue, and VIII-X from repeat 2 in cyan). The remaining helices and loops are omitted for clarity. The 2 Na ϩ and the I Ϫ are shown at positions inferred from experimental data and molecular dynamics calculations.
and VIII (136) . The betaine in BetP is confined between 3 tryptophans and a tyrosine from TMSs II and VI (178) . For Na ϩ -driven transporters, the Na ϩ to substrate stoichiometry varies. For example, LeuT and BetP transport 2 Na ϩ to 1 substrate, whereas vSGLT and Mhp transport 1 Na ϩ to 1 substrate. LeuT was the only structure where the Na ϩ sites (Na1 and Na2) could be unequivocally identified, owing to the high resolution at which it was determined (1.65 Å). Na1 is coordinated directly by the carboxylate oxygen of the substrate, whereas Na2 is located at the intersection of TMSs I and VIII and is coordinated by the main-chain carbonyl oxygens from the unwound portion of TMS I and the OH Ϫ groups from Ser and Thr from TMS VIII as described above. The Na2 site is conserved in all 4 structures and is located ϳ8 Å from the substrate binding site.
D. Position 93 is critical for NIS substrate specificity and stoichiometry
The NIS homology model generated using the x-ray structure of vSGLT (20) as a template has provided vital information on the mechanism of NIS, as was clearly shown in connection to the analysis of position 93 (71) . The study of the G93R NIS mutant started with the identification of a patient who developed goitrous hypothyroidism due to ITD (180) . The patient actually had a compound heterozygous G93R/T354P NIS mutation, having inherited the G93R substitution from his mother and the T354P from his father (181). Paroder-Belenitsky et al (71) undertook a detailed study of the role of position 93 in NIS by carrying out various amino acid substitutions at this position and assessing the effect of the substitutions on the activity and behavior of the protein. They determined that G93R NIS was targeted to the plasma membrane but was inactive and showed that the cause of the lack of activity was not the presence of the positively charged Arg residue, as G93K NIS was not only functional but also accumulated I
Ϫ at values comparable to those of WT NIS. They reported that the longer the side chains of substituted neutral residues at this position, the higher the protein's K m values for I Ϫ . G93N and G93T NIS exhibited Ͼ18-fold higher K m values for I Ϫ than WT NIS, and G93Q NIS had an astonishingly Ͼ200-fold higher K m for I Ϫ (6.1 mM). actively translocated by G93T/N NIS and that the process is electrogenic (Table 3 ). In addition to G93T and -N, G93D, -E, and -Q also transport ReO 4 Ϫ and ClO 4 Ϫ electrogenically ( Figure 9 ). Finally, whereas G93E and G93Q NIS also transported ReO 4 Ϫ and ClO 4 Ϫ , their ability to transport I Ϫ was severely impaired, strongly suggesting that each of these 2 amino acids at this position confers to the molecule the ability to discriminate between anion substrates (Table 3 ). In conclusion, position 93 appears to be a key Na ϩ /anion coupling link (129) that controls both transport stoichiometry and anion substrate specificity. As briefly stated above, a 3-dimensional homology model of NIS was built using as a template the available x-ray structure of vSGLT (135) . In the NIS homology model, TMSs III and X are at the edge of the molecule, in , although to a lesser extent than WT NIS. Expression levels and plasma membrane targeting were not responsible for the lack of activity of W255A NIS, as it was equally expressed and properly targeted to the cell surface, as assessed by immunoblot and flow cytometry under nonpermeabilized conditions. The lack of activity was also shown with other substrates, as W255A did not transport ReO 4 Ϫ either, even at very high concentrations.
The NIS homology model offers a rationale for the above-described effects of amino acid substitutions at position 93 on NIS activity, substrate specificity, and stoichiometry. The change from the inwardly to the outwardly facing conformations of the protein is best described as a 25°to 30°rotation of the TMS II-III helical hairpin, which, strikingly, pivots around the contact between G93 and the indole ring of W255 (71) . Residues 118 to 132, which connect to the helical hairpins, provide a key structural element that permits the rotation of the 2 hairpins with small variations in their respective structures. As the conformational transition changes the distance between the end of TMS III and the beginning of TMS IV, the connecting residues must accommodate this change. Residues 118 to 132 are ideally suited for this task. This region consists of a short helix flanked by 2 short unstructured stretches. The change in distance between the ends of the 2 hairpins is easily accommodated by a rotation of the short helix with small changes in the connecting pieces acting as hinges. The large displacement of the C terminus of TMS III pushes, via the connecting rod, the short helix, resulting in a large displacement of its N-terminal portion, whereas its C terminus acts as a hinge for the rotation of Ϫ and ReO 4 Ϫ do not elicit any current (traces in green box). However, the experiments described in Figure 6 showed that ClO 4 Ϫ and ReO 4 Ϫ are transported by NIS, with a V max that is only approximately one-third that of I Ϫ , which would have produced currents of recordable magnitude. Therefore, it is concluded that ClO 4 Ϫ (and ReO 4 Ϫ ) transport occurs with a different stoichiometry (1 Na ϩ to 1 ClO 4 Ϫ /ReO 4 Ϫ ) than that of I Ϫ transport and that it is electroneutral. Interestingly, it is possible to modify the Na ϩ /anion transport stoichiometry by replacing a single amino acid in TMS III ( Figures 2 and 7) ; G93N/T/D/Q/E NIS, for example, transports ClO 4 Ϫ and ReO 4 Ϫ in an electrogenic fashion (yellow rectangle).
the helix and does not move significantly, allowing TMSs IV and V to remain close to their original positions. TMS VII, in the second half of NIS, which encompasses W255 (the residue against which G93 rests), runs at an angle with respect to TMS IV. As the rotation takes place, TMS VII has to move away as part of the overall conformational change (71) . These proposed conformational changes are compatible with previously proposed models (177, (182) (183) (184) . Thus, the nature of the side chain at position 93 of NIS may control the extent as well as the final state of the transition between the outwardly and the inwardly open conformations and play a role in the kinetic parameters as well as the stoichiometry of the protein. It is worth pointing out that the significance of position 93 would have remained unknown had it not been for the naturally occurring mutation found in the ITD patient. These findings may have implications for other proteins, as positions equivalent to G93 of NIS in other transporters may have a similar function (71) . The discovery that by manipulating position 93, NIS molecules may be engineered to selectively transport some anion substrates and not others may be applicable to NIS-based gene transfer efforts, in which an optimally tailored molecule cold be used in cancer treatment (see Section IX.E.).
E. The study of the ITD-causing NIS mutation ⌬439 -443 provided novel information on helix capping
The study of the ITD-causing NIS mutation ⌬439 -443 (deletion of amino acids ACNTP) has also shed light on properties of specific amino acid residues. This mutation, first described in an Italian patient with CH, is putatively located in the intracellular loop between TMSs XI and XII ( Figure 7 ) (185). ⌬439 -443 NIS is retained intracellularly. Engineering 5 Ala at these positions markedly improves membrane targeting and even restores some of its activity. Remarkably, although the recognition of the ⌬439 -443 mutant by an anti-NIS antibody, directed against a conformational epitope on the last third of the protein, is compromised, reactivity is restored upon introduction of the 5-Ala stretch. This strongly suggests that the ⌬439 -443 significantly alters NIS tertiary structure. Using the NIS homology model, Li et al (168) determined that the length of the sixth intracellular loop between TMSs XI and XII is ϳ12 Å, and proposed that the amide hydrogen in the main chain at the beginning of TMS XII is capped by the side chain of N441 (one of the residues missing in this deletion). For the ⌬439 -443 mutant, this distance is significantly shorter. Bringing the carboxy terminus of TMS XI and the amino terminus of TMS X together requires large changes in the orientation of the 2 helices and the entire protein. These changes produce a NIS molecule that is neither targeted to the plasma membrane nor functional. The 5-Ala mutant may form a helix that increases the distance to 5 to 7 Å, minimally rescuing targeting. Interestingly, in the background of the 5-Ala mutant, both N441 and Q441 yield proteins that behave like WT NIS, completely restoring membrane targeting and activity, suggesting that TMS XII in these mutants is capped. Moving the N just 1 residue over, N440, does not restore WT properties (168) . N441 is extremely conserved in the SLC5 family, and its function is likely to be as well.
VII. Functional Expression of NIS in Extrathyroidal Tissues
Extrathyroidal accumulation of I Ϫ has been reported in the salivary glands, gastric mucosa, small intestine, lactating mammary gland, choroid plexus, and the ciliary body of the eye (127, 186) . However, in contrast to the thyroid, I Ϫ is not organified and I Ϫ uptake is not regulated by TSH in these tissues ( Table 2 ). Albeit NIS mRNA has been detected in various other tissues, such as colon (187), ovaries (188), uterus (189) , and spleen (188) by RT-PCR, functional NIS expression or subcellular localization in these tissues has not been established. Thus, the role and importance of NIS in these tissues is unclear (24, 122, 190, 191) . We will focus on tissues where NIS expression has been functionally characterized.
A. Salivary glands
The ability of the salivary glands to concentrate I Ϫ is an important diagnostic tool for the detection of thyroid disorders in newborns through the saliva to plasma I Ϫ ratio.
NIS protein expression has been unequivocally shown at the basolateral surface of ductal epithelial cells. The physiological role of I Ϫ secretion in the saliva and gastric juices is a matter of debate. A role in recycling of the body I Ϫ pool has been suggested (192) . I Ϫ that has not been taken up by the thyroid or I Ϫ released by the action of deiodinases is secreted into the saliva and gastric juice to be reabsorbed by the small intestine. Given its antioxidant properties, I
Ϫ may act as an antimicrobial agent in saliva and gastric juice as well, and in saliva, I Ϫ has been reported to enhance epidermal growth factor levels, which promotes mucosal healing and intestinal growth (193, 194) . A bactericidal/bacteriostatic effect is consistent with the presence of an H 2 O 2 /peroxidase system in the salivary glands. Interestingly, Duox2 mRNA was detected in salivary glands by in situ hybridization (195) . The H 2 O 2 generated by this enzyme is used by lactoperoxidase (LPO), a heme-dependent secreted peroxidase produced by the submucosal glands, which is also abundantly secreted in saliva, to oxidize SCN Ϫ (a NIS substrate) to hypothiocyanite (OSCN Ϫ ), which is present in human saliva at micromolar 
B. Stomach
NIS is expressed on the basolateral surface of mucinsecreting and parietal cells in the stomach. As NIS is expressed on the basolateral surface of gastric mucosal cells, NIS mediates the active uptake of I Ϫ from the blood into the gastric epithelial cells from where it is secreted into the gastric juice. Therefore, gastric NIS plays no role in the absorption of dietary I Ϫ . Interestingly, gastric NIS expression is downregulated in gastric cancer as well as intestinal metaplasia (197) . This observation suggests that the decrease in NIS expression may be a marker for the diagnosis and possibly evaluation of the prognosis of stomach cancer patients.
C. Small intestine
NIS is also present in enterocytes of the small intestine, where dietary I
Ϫ is absorbed (198) . Using intestinal brush border membrane vesicles, Nicola et al (198) showed that the K m for Na ϩ -dependent, ClO 4 Ϫ -sensitive I Ϫ transport in small intestine is comparable to that of thyroid cells (ϳ10M-30M). Pertechnetate (TcO 4 Ϫ ), a NIS substrate, is transported by the small intestine in a ClO 4 Ϫ -sensitive manner in vivo. In contrast to other NIS-expressing tissues, NIS in the small intestine is targeted apically. It is therefore plausible that I Ϫ secreted into the saliva and the gastric juice is reabsorbed and recycled via NIS in the small intestine, together with the dietary I Ϫ pool. Although a contribution from other I Ϫ -permeable transporters and channels (eg, Cl Ϫ channels and pendrin) that may be present in the intestine cannot be formally excluded, it must be noted that these transporters have a K m for I Ϫ transport at least two orders of magnitude higher (in the mM range) than the concentration of I Ϫ in most foods. Recently, SMVT has been reported to transport I Ϫ with a K m of ϳ150M in voltage-clamped oocytes (199) . The main characterized function of SMVT in the intestine is biotin transport at the brush border of enterocytes (200) . However, the contribution of SMVT to I Ϫ absorption under physiological conditions in vivo remains to be determined. In addition, intestinal NIS expression is decreased by high I Ϫ in the diet, just as it is in the thyroid. High I Ϫ downregulates NIS protein expression and I Ϫ uptake in the small intestine in a time-dependent manner in vivo, as assessed in brush border membrane vesicles isolated from rats treated with 0.05% KI in their drinking water. After 12 hours of high I Ϫ supplementation, NIS protein levels decreased by ϳ50% and after 24 hours by ϳ80% (198) . Therefore, it seems that NIS downregulation after high I Ϫ exposure is an autoregulatory mechanism to protect the thyroid or other I Ϫ -transporting tissues from the possibly deleterious consequences of I Ϫ overload. It will be interesting to investigate whether this mechanism occurs in other NIS-expressing tissues, including tumors.
D. Lactating breast
NIS expression in normal breast occurs only during pregnancy and lactation, when cell proliferation occurs. I Ϫ secreted into the milk is the sole source of this nutrient for the newborn and is critical for his/her normal thyroid function, as discussed above (122) . The electrophoretic mobility of breast NIS (116) is generally higher than that of thyroid NIS as a result of differences in glycosylation. As discussed in Section IX.C.1. of this review, NIS expression was also found by Tazebay et al (116) in Ͼ80% of human breast cancers as well as in several transgenic animal models of mammary adenocarcinomas. Of note, NIS is not regulated by TSH in the breast. This property has a potential medical impact in the development of a treatment for NIS-expressing breast tumors with radioiodide, as it allows downregulation of NIS in the thyroid but not in the breast, thus protecting the healthy thyroid from the radioisotope (Section IX.C.) (201) .
E. Kidney
I Ϫ is excreted through the kidneys, and UI is the simplest method to assess ID. However, the mechanism of UI excretion remains a subject of controversy. Full-length NIS mRNA was detected by RT-PCR followed by Southern blot hybridization in human kidney tissue (202) . These authors reported NIS immunoreactivity along the full length of the nephron, with the exception of the glomerulus. Basolateral staining was predominant in the proximal tubular cells, whereas cytoplasmic and more diffuse staining was apparent in the distal ones. Immunohistochemical studies by other groups did not reveal NIS expression in the kidney (190, 203) . A study performed on high-density tissue microarrays (204) showed NIS expression at the apical surface of the collecting duct. None of these studies described NIS activity in the kidney, with the exception of a human kidney tumor epithelial cell line (G401) derived from Wilms' tumor (202) , in which the hallmarks of NIS activity (Na ϩ -dependent, ClO 4 Ϫ -sensitive I Ϫ uptake) were demonstrated (202) . In summary, the existence of functional expression, localization and regulation of NIS in the kidney is still an open question, which will be interesting to address to better understand the fate of I Ϫ in the body and how the I Ϫ balance and supply to the thyroid are modulated.
F. Placenta
Importantly, low levels of NIS expression have been reported by immunohistochemistry in different subtypes of placental cells, where NIS likely mediates transplacental I Ϫ translocation for fetal TH biosynthesis (205) (206) (207) .
However, the level of NIS expression varies dramatically from sample to sample, and neither membrane localization nor activity has yet been shown definitively, although a nonpolarized pattern of expression in the cytotrophoblast has been observed (207) .
G. Airway mucosal surface host defense: a new role for NIS?
In addition to being essential for TH biosynthesis, I
Ϫ plays a role in innate antimicrobial defense. It has been shown that, when applied to human or porcine primary airway epithelium, I
Ϫ inhibits viral infection by both encapsidated and enveloped respiratory viruses (72 from nonaffected subjects showed a 10-fold higher concentration in the apical chamber after incubation with 40M SCN Ϫ .
The temporal and causal relationship between lung inflammation and infection has been unclear for a long time; mouse animal models generated in the past do not recapitulate the features of the human disease. However, a defect in the primary mucosal surface host defense system seems to be one of the first pathogenic events in CF, as recently found in CFTR Ϫ/Ϫ and CFTR Ϫ/⌬508 pigs (210).
Lungs of newborn transgenic or KO pigs contain bacteria more often than control pigs and contain a higher number of bacteria, with no signs of inflammation at early stages, indicating a defect in early lung bacterial clearance. In a study investigating the identity of the basolateral SCN Ϫ transporter in primary human airway cultures (211), the authors found that basolateral-to-apical SCN Ϫ transport is ClO 4 Ϫ -sensitive, competes with I Ϫ , and is dependent on Na ϩ , which is highly suggestive of NIS-mediated transport. In addition, the kinetic characteristics for transport of these anions were compatible with those reported for NIS. In support of this notion, immunofluorescence with an anti-NIS antibody revealed a signal in the submucosal glands, probably at the basolateral surface, although there was no immunoblot to confirm the specificity of the antibody signal. In addition, NIS mRNA has been found in lung (189, 203) .
Taken together, these results contribute to the elucidation of the role of SCN Ϫ /I Ϫ transport together with LPO/ H 2 O 2 , respectively, in an antibacterial or antiviral host defense system in the lung. They also link a defect in SCN cosal surfaces (Figure 10 ). Whether SCN Ϫ or I Ϫ transport defects account for at least the initial pathogenic events in CF is a fascinating question that must be investigated.
VIII. Regulation of NIS in the Thyroid and Extrathyroidal Tissues
Here we concentrate on NIS regulation by TSH and I Ϫ , by a novel mechanism involving the potassium voltage-gated channel, KQT-like subfamily member 1 (KCNQ) 1/ KCNE2 K ϩ channel, and by lactogenic hormones. For NIS regulation by Tg, a negative feedback mechanism involving the downregulation of several thyroid-specific transcription factors, the reader is referred to the 2011 review by Suzuki et al (212) . For a comprehensive overview of transcriptional regulation of NIS, the reader is referred to a recent review by Kogai and Brent (213) .
A. By TSH
The thyroid-pituitary-hypothalamic axis regulates TH production, and its integrity is critical for metabolic homeostasis. TH secretion is activated by TSH, a glycoprotein produced by thyrotrophs in the anterior pituitary and the major regulator of thyroid function. TSH consists of 2 subunits: the ␣-subunit is identical to that of the other 3 hormones synthesized by the anterior pituitary (LH, FSH, and CG), whereas the ␤-subunit is unique and confers functional specificity. TSH release is stimulated by TRH, a tripeptide (pyro-Glu-His-Pro-NH 2 ) produced by the parvocellular neurons in the hypothalamus as a preprohormone (pre-pro-TRH), which, in humans, consists of 6 copies of the TRH sequence that are cleaved to yield mature TRH (43) . THs, in turn, act via a negative feedback mechanism to downregulate production of both stimulating hormones. In the absence of a sufficient I Ϫ supply, THs Ϫ is translocated across the basolateral membrane by NIS, using the Na ϩ electrochemical gradient generated by the Na -activated Cl Ϫ channels (CaCC), and pendrin, which is also expressed in airway epithelial cells, are also responsible for SCN Ϫ translocation, in particular under conditions that increase their expression (for instance, under the stimulation of IL-4, an anti-inflammatory cytokine) (342) . Duox1, which is expressed at the apical surface in airway epithelium, generates H 2 O 2 , a substrate for the oxidation by LPO of SCN Ϫ to OSCN Ϫ , a species that has antibacterial activity. I Ϫ at the cell air/liquid interface has also recently been found to have an analogous and complementary function; it reduces viral infection in the airway epithelia in vitro (336) .
cannot be synthesized, and continuous stimulation by TSH leads to goiter, an enlargement of the thyroid gland. Thyroid function is mainly regulated by TSH, which acts via the TSH receptor. This receptor is a 7-TMS protein at the basolateral surface of thyrocytes, coupled to a heterotrimeric G protein. cAMP, produced from the G s␣ -mediated activation of adenylate cyclase, stimulates NIS transcription (214, 215) . In addition to NIS, TSH also upregulates expression of TPO and Tg as well as iodinated Tg endocytosis. Levy et al (113) have shown that thyroid NIS protein expression is upregulated by TSH in vivo.
A TSH-mediated increase in NIS expression and I Ϫ accumulation was demonstrated in FRTL-5 cells and human thyroid primary cultures (214, 216, 217) . Withdrawal of TSH from FRTL-5 cell media results in reduction of both cAMP levels and I Ϫ transport activity (24, 118, 121, 218 (Figure 11A ). However, this inhibitory effect of I Ϫ lasts ϳ2 days in the presence of high plasma I Ϫ , after which TH biosynthesis is restored (221) . This adaptation to persistent high I Ϫ was termed the escape from the Wolff-Chaikoff effect ( Figure 11B ). Significantly, adapted thyroids accumulated less I Ϫ than nonadapted thyroids, which rescued thyroid function. This led Braverman and Ingbar (222) to suggest that the escape from the Wolff-Chaikoff effect was mediated by a reduction in I Ϫ transport ( Figure   11B ), which would alleviate the high intracellular I Ϫ concentrations and restore TH biosynthesis. What is the mechanism for the escape/decrease in I with NIS activity (226) . Thus, the Wolff-Chaikoff effect and its escape constitute an intrinsic autoregulatory mechanism to protect the thyroid gland from the deleterious effects of I Ϫ overload.
The escape from the Wolff-Chaikoff effect is unquestion- ably mediated by inhibition of I Ϫ transport. Recent data are consistent with the hypothesis that the NIS mRNA half-life is reduced by a posttranscriptional mechanism at least at short time points, rather than a change in NIS promoter activity (227) . In addition, I Ϫ excess was also found to trigger an increase in ROS production and in the expression and activity of ROS-scavenging selenoenzymes (228). The results described above point to both a posttranscriptional and a posttranslational component to the escape mechanism and suggest that the presence of high I Ϫ , which is oxidized intracellularly through an unknown mechanism, inhibits thyroid function. However, various possibilities exist that could explain the reduction in NISmediated I Ϫ accumulation. As indicated by these authors (228) , although an attractive hypothesis, it remains to be determined whether the redox state of thyroid cells and its potential effect on amino acid modifications or oligomeric state directly modulate NIS activity. Another question open to investigation is whether, in addition to effects on NIS mRNA, high I Ϫ concentrations also modulate NIS protein biogenesis, subcellular localization, and degradation.
Significantly, it was recently demonstrated that I Ϫ -induced NIS downregulation is not a thyroid-specific phenomenon, because it occurs also in small intestine enterocytes (198) (Section VII.C.) .
High concentrations of I Ϫ , presumably in the form of iodolipids, inhibit the generation of H 2 O 2 (229 -231). Interestingly, iodolipids have been found in rat, horse, dog, and human thyroid. These iodolipids inhibit Duox and adenylyl cyclase, suggesting that they are involved in regulatory actions of I Ϫ in the thyroid (232, 233) .
C. By a novel mechanism involving a K ؉ channel
Roepke et al (234) have demonstrated for the first time that an ion channel plays a key role in thyroid function. Specifically, these authors reported that the ␤-subunit (KCNE2) of the voltage-gated potassium channel KCNQ1/KCNE2 is required for TH biosynthesis. This channel is a complex comprising 4 large KCNQ1 subunits, which traverse the membrane 6 times each, and 2 small KCNE2 subunits, which traverse the membrane only once each (235) . KCNQ1/KCNE2 K ϩ channels participate in the repolarization of the cardiac ventricles (235) . The regulation of NIS by this channel was uncovered when mice in which the Kcne2 gene had been genetically deleted (Kcne2 Ϫ/Ϫ mice) presented not only cardiac symptoms (cardiomegaly, hypertrophy, and impaired contractility) but also several other, unexpected symptoms including alopecia, a 50% embryonic death rate, and growth retardation resulting in dwarfism. These findings led Roepke et al (234) to determine the thyroid status of these mice; they C293B did not have any effect on I Ϫ uptake when NIS was expressed in COS cells, which do not express endogenous KCNQ1/KCNE2 K ϩ channels.
The localization of KCNE2, like that of NIS, varies with tissue type. Thus, although KCNE2 is basolaterally targeted in thyrocytes, it is apically expressed in the gastric parietal cells (238) . That NIS is regulated by KCNQ1/ KCNE2 has potential relevance to human cardiac function, given that cardiac manifestations observed in patients with mutations in KCNQ1 or KCNE2 may have an endocrine component. Clearly, one question that emerges is how KCNQ1/KCNE2 regulates NIS function. One possibility is that the activity of this channel is critical for maintaining the membrane potential in thyroid cells. If this is so, then alteration of KCNQ1/KCNE2 by either genetic or pharmacological means will decrease the membrane potential. Because this potential is part of the driving force for NIS-mediated I Ϫ uptake (which is electrogenic), such a decrease would impair NIS activity. The molecular mechanism involved in the regulation of NIS by KCNQ1/KCNE2 will likely be elucidated by a combination of genetic, pharmacological, biochemical, and biophysical approaches.
D. By lactogenic hormones
Although absent in nubile rats, NIS expression in the mammary gland progressively increases toward the end of gestation and is most prominent during lactation. Hormonal regulation of rat mammary gland NIS has been studied both in vitro and in vivo. NIS expression is reversibly regulated by suckling during lactation. In vivo studies in ovariectomized mice revealed that the combination of ␤-estradiol, oxytocin, and prolactin results in the highest level of NIS expression in the mammary gland (116) .
IX. Clinical Applications of NIS
A. Hyperthyroid states
Radioiodide therapy has been successfully used in the treatment of hyperactive thyroid states such as Graves' disease and toxic nodular goiter for over 60 years. Its use in these benign thyroid diseases is thoroughly reviewed by Bonnema and Hegedüs (239) . Briefly, although 131 I Ϫ is still used to treat Graves' disease, antithyroid drugs have replaced it as the preferred treatment, largely because 131 I Ϫ can cause hypothyroidism. It has been reported that although hyperthyroidism is cured in 50% to 90% of those treated within 3 to 12 months of 131 I Ϫ treatment, hypothyroidism is observed with an incidence of 5% to 50% within the first year of treatment in those patients (239) . Patients with toxic nodular or multinodular goiters also benefit from 131 I Ϫ ablation and exhibit lower rates of hypothyroidism. Some European countries currently preferentially use 131 I Ϫ to treat patients with benign nontoxic goiter (239).
B. Thyroid cancer
Over 44 000 people in the United States are estimated to have been diagnosed with thyroid cancer in 2010 (240), an incidence that has more than doubled since the 1970s. Thyroid cancer is the fastest rising among malignancies and accounts for 5% of newly diagnosed cancers among women. The follicular or papillary variants of differentiated thyroid cancer are the most common endocrine malignancies. Mutations in proteins along the MAPK signaling pathway are also found in thyroid cancer. Altogether, mutations in RET, all 3 RAS isoforms, and BRAF are found in ϳ70% of all thyroid cancers (241, 242) . Constitutive activation of these proteins stimulates the MAPK signaling pathway, inhibiting the expression of proteins involved in the TH biosynthetic pathway, including NIS. Tellingly, BRAF mutations are commonly found in sporadic papillary thyroid cancer (PTC), but not in radiationinduced, RET/PTC-positive PTC, indicating that RET/ PTC and BRAF very likely reside in the same signaling pathway (243) . Mutations in upstream proteins lead to activation of other signaling pathways, whereas BRAF mutations (ϳ45% of PTCs) result in the activation of the 2 known effectors, MAPK kinase 1 (MEK1) and MEK2. In contrast to melanoma, where the correlation between BRAF mutations and poor prognosis and survival is controversial (although there is a clear association with invasiveness), in thyroid cancer, there is a well-recognized association between BRAF mutations and a less favorable prognosis (invasiveness, cancer recurrence, lymph node metastases, and advanced stage at presentation) (244) . Virtually all BRAF mutations in PTC result in the production of a constitutively active BRAF
V600E
. BRAF V600E is thought to be involved in promoting cell survival and proliferation by hyperphosphorylation of retinoblastoma protein (Rb) (which promotes the cell cycle transition from G1 to S phase by releasing the inhibition of elongation factor 2 [E2F]-dependent transcription) (244) . Interestingly, in many cases, oncogenic BRAF mutations alone are not enough to drive transformation in vivo and in vitro: in fact, most micro-PTCs (precursors of PTC) and benign nevi (precursors of melanomas) carry oncogenic BRAF. Expression of physiological levels of BRAF V600E in a lung mouse model induced adenocarcinomas when mice were crossed with mice carrying inactivating mutations of p53 or p16/Ink4a, suggesting that a second, senescencebypassing mutation is required. Overexpression of mutated Harvey rat sarcoma viral oncogene homologue (H-Ras) in thyroid cells is also not enough to promote cell transformation. In PTC, however, mutations in p16 or p53 are virtually never found (although they are common in anaplastic thyroid cancer). However, thyroid knock-in of BRAF V600E in mice results in short-latency, invasive PTC (244) . It has been suggested that because activated BRAF decreases TH biosynthesis, the resulting high blood concentration of TSH may play a role in tumor development. This suggestion is consistent with the well-established clinical observation that TSH and tumor develop-ment are associated (an association, however, whose molecular underpinnings are not known in detail).
Notably, PTCs harboring BRAF V600E have absent or decreased NIS-mediated 131 I Ϫ uptake. Conditional exogenous expression of RET/PTC3, which induces activation of MAPK signaling, decreases NIS protein expression in rat thyroid cells (PCCL3), an effect prevented by silencing RNA knockdown of BRAF, but not other RAF isoforms (244, 245) . Doxycycline-induced BRAF V600E expression in PCCL3 cells induces mistargeting and lower expression of NIS, an effect that is reversed by removal of doxycycline or treatment with MEK inhibitors. Interestingly, NIS plasma membrane expression is also restored in vivo in animals harboring doxycycline-inducible, thyroid-specific knock-in BRAF V600E upon administration of MEK inhibitors or specific BRAF V600E inhibitors or by switching off BRAF V600E expression by doxycycline removal. Importantly, restoration of I Ϫ uptake has been shown by micro-PET and quantitative dosimetry as well as an increase in apoptosis and DNA damage upon 131 I Ϫ administration (246) . The availability of thyroid cancer mouse models recapitulating the characteristics of the human disease has been crucial in unveiling signaling pathways that are key in tumor initiation and progression and will undoubtedly help in identifying novel drug molecular targets. Clinical trials are currently ongoing to determine whether MEK inhibitors increase 131 I Ϫ uptake (247) (248) (249) (250) (251) (252) .
Most recently, a clinically significant increase in radioiodide uptake and retention was reported in a trial with selumetinib, a selective allosteric MEK1 and MEK2 inhibitor, in patients with thyroid cancer refractory to radioiodide. ing part of the tumor can be destroyed and the surrounding undifferentiated tissue can be reached by a ␤-particle cross-fire effect (256) . Side effects are common but generally mild: nausea, posttreatment neck pain, sialadenitis, taste alteration, and pulmonary fibrosis (in the repeated treatment of lung metastases). Increased risk of radiation-induced leukemia is controversial and probably associated with extremely high doses that were more commonly administered in the past (254) .
Patients with thyroid carcinoma have an overall 97% 5-year survival rate (257) , and in numerous retrospective studies on large numbers of patients, radioiodide therapy was found to be the most powerful indicator for diseasefree survival (258) and to decrease recurrence rates and tumor-specific deaths (254, 256, 259) . In addition, radioiodide uptake in distant metastases was found to increase survival rate at 10 years from 10% to 56% (259).
C. Emerging roles of NIS in extrathyroidal pathologies: endogenous NIS expression and exogenous NIS expression by gene transfer
Breast cancer
In 2000, NIS expression was demonstrated in Ͼ80% of human breast cancers and in several transgenic animal models of mammary adenocarcinomas (116) . Significantly, NIS is functionally expressed in human breast cancer metastases, as assessed by scintigraphy (201) . NIS is also expressed in triple-negative (estrogen receptor-, progesterone receptor-, and Her2-negative) breast cancers (65% of cases), for which the therapeutic choices are limited to chemotherapeutic agents (260) . These observations suggest that 131 I Ϫ may prove to be a useful tool in breast cancer therapy. A recent study analyzed NIS expression in breast cancer brain metastases. Brain metastases constitute a therapeutic challenge because of the impermeability of the bloodbrain barrier to most chemotherapeutic agents, which limits the therapy to surgery and external radiation. As a result, the prognosis of breast cancer brain metastasis patients is poor (2.3-to 7.1-month median survival). It has been reported that 75% of total cases and 80% of HER2 ϩ metastases expressed NIS. Although NIS expression was largely intracellular, plasma membrane expression was detected in 24% of NIS-positive samples (261) . Although these observations are promising, whether the degree of 131 I Ϫ accumulation by breast tumors and their metastases will be sufficient for successful therapy needs to be thoroughly evaluated.
Various factors must be considered in applying 131 I Ϫ therapy to breast cancer. As different tumor types may have different sensitivity to radiation, the clinical outcome of a similar dose could differ between thyroid and breast cancer, and a smaller radiation dose might be sufficient to elicit a therapeutic effect in breast cancer cells. Second, it has been noted that tumor NIS positivity changes over time (201, 260) as a result of disease progression and/or treatments. Therefore, it is of interest to study tumor-specific radioiodide accumulation in breast cancer patients who have not undergone extensive treatment and in primary tumors. In addition, the use of another NIS substrate, 188 ReO 4 Ϫ , could also increase the radiation dose delivered to the tumor (discussed in Section IX.E). Liu et al (262) have reported NIS expression in cholangiocarcinoma, only the second extrathyroidal cancer, after breast cancer, to be found to express the protein endogenously. Considering that currently available therapies for cholangiocarcinoma are not effective (the 5-year survival rate for cholangiocarcinoma patients is only 2%), this discovery raises the notion that NIS-mediated radioiodide therapy should be investigated as a potential new treatment.
The upregulation and mislocalization of NIS in various tumor types has sparked interest in the role that these phenomena play in carcinogenesis. Recent studies by Lacoste et al (263) have suggested that the expression of NIS, and not its translocation of ions, is involved in upregulating cell migration and invasion via binding to leukemiaassociated RhoA guanine exchange factor and activation of the small GTPase RhoA. It will be extremely interesting to investigate how wide a variety of tumors display upregulation of cell migration and invasion by NIS.
NIS as a reporter gene
PET-based imaging using reporter genes is a powerful technique that allows monitoring of gene delivery and adoptive-cell therapies (ie, T cell and stem cell transfers) (264) . For gene transfer, reporters enable quantitative monitoring of the location of viral vectors and the extent and duration of transgene expression, whereas for cell therapy, they permit monitoring of the targeting and location of the transplanted cells. For a complete review of the advances in using NIS as a reporter gene, please refer to Penheiter et al (265) . Here we discuss some highlights.
NIS is an extremely useful human reporter gene, whose use as an imaging modality is more than promising. Unlike receptors, which can bind ligands with only a 1:1 stoichiometry, NIS, being an active transporter, accumulates its radiolabeled substrates and concentrates the signal. This is highly desirable; otherwise, weak transgene expression would be difficult to detect. Furthermore, radiotracers already approved for clinical use in both PET ( (264) . NIS can be used to monitor not only its own delivery but also that of other genes, and potentially the size of the tumor, given that once NIS is expressed in the target tissue/tumor, diagnostic scintigraphic imaging can be performed (266 -268) . Several reports in recent years highlight the feasibility and potential of this strategy (269 -273) , particularly in oncology. NIS may prove to be a useful reporter in the arena of pulmonary gene therapy. In 2005, Niu et al (274) used adenoviral (Ad)-hNIS delivered intranasally into the lungs of Cotton rats and were able to detect 124 I Ϫ PET signal up to 17 days after administration of the vector. Thus, NIS may potentially be helpful in monitoring the delivery of therapeutic genes for lung disease such as CFTR for CF. However, intranasal administration of any foreign substance in human subjects may prove to not be trivial, because induction of anaphylaxis can be a fatal complication. The feasibility of using NIS for cardiac gene expression imaging has also been demonstrated in animal models (275) (276) (277) (278) (279) . Safety for myocardial injection was evaluated by echocardiography, serial creatine kinase measurements, and a histologic examination in rats.
Reporter genes are useful for tracing the localization of transplanted cells. In 2008, Terrovitis et al (280) was reported in this study (283) . Both these factors underscore the importance of developing methods of increasing NIS expression and membrane targeting, as well as I Ϫ retention, to make it possible to most effectively use NIS as a reporter gene in vivo.
NIS as a therapeutic gene
Although the reporter properties of NIS have been explored, most studies have focused on the protein's therapeutic potential in a variety of cancers in animal models. Here we highlight some of the exciting results that have been obtained in the field. For a more comprehensive summary on the topic, the reader is referred to recent reviews (213) .
Radioisotopes are used clinically in 2 forms, as sealed and unsealed sources. A sealed source is one that is surrounded by an inert cover and is delivered to either the surface or inside of a tumor and is used to administer brachytherapy. After treatment, the radioactive source is removed from the patient. In this case, the patient never comes into direct contact with the source and remains cold. In contrast, unsealed sources are not encapsulated. They are administered through ingestion or injection and do come into direct contact with the patient. Thus far, the use of unsealed sources is limited to a few malignancies, including thyroid cancer ( in the tumor (6 hours) (289) . Since then, more efficient ways to deliver NIS using viral vectors have been exploited and promising results obtained. The potential and feasibility of NIS in gene therapy has been extensively evaluated in numerous preclinical studies. Introduction of NIS via gene transfer has been undertaken by several groups to render tumors susceptible to 131 I Ϫ treatment. Success with this approach has been reported both in vitro and in vivo in liver, prostate, colon, ovarian, pancreatic, and cervical carcinomas and in melanoma, glioma, and multiple myeloma (24, 25, 122, 269 -273, 290 -306) .
Particularly interesting results have been obtained with hepatocarcinoma, prostate cancer, and multiple myeloma. NIS gene transfer has been used in an aggressive model of hepatocarcinoma induced by diethylnitrosamine in immunocompetent rats. Injection of an adenoviral vector expressing NIS under the cytomegalovirus (CMV) promoter (Ad-CMV-NIS) into the portal vein of hepatocarcinoma-bearing rats followed by 131 I Ϫ therapy resulted in a strong inhibition of tumor growth and prolonged survival (270, 304) . Although rapid efflux was reported in vitro, sustained uptake was observed for Ͼ11 days in vivo. The authors attributed this to the recycling of effluxed I Ϫ through the portal circulation. Notably, despite the use of the ubiquitous CMV promoter, the inherent tropism of adenovirus for the liver and the intraportal route of injection allowed for a rather targeted delivery.
The success of NIS gene transfer therapy depends on efficient delivery of the NIS gene into the target tissue and proper NIS expression at the plasma membrane, a requirement for 131 . The study demonstrated the successful introduction of localized functional NIS expression to the prostate without radiation damage or vector-related toxicity to other cells or organs. At the time of writing, a clinical trial using Ad-NIS for prostate cancer is ongoing at the Mayo Clinic, indicating the potential of the NIS gene transfer approach.
A self-inactivating lentiviral vector with NIS under the Ig promoter has been used by Dingli et al (269) to selectively target multiple myeloma cells. Strikingly, in this study, tumor xenografts expressing NIS were completely destroyed by a single dose of 131 I Ϫ (1 mCi) and sustained complete tumor regression up to 5 months after treatment, the longest follow-up reported to date. This group also evaluated the bystander effect of 131 I Ϫ therapy by injecting tumor xenografts consisting of a mixed population of NISexpressing and non-NIS-expressing cells (50:50 and 10: 90). Remarkably, the xenografts that expressed NIS in only 50% of cells completely resolved, whereas those that expressed NIS in only 10% still displayed slower growth than those not expressing NIS. This is an extremely important observation, because the efficiency of viral transduction in vivo is far from 100%. These results demonstrate the potential of NIS as a transgene, as the bystander effect of NIS-mediated 131 I Ϫ therapy can potentially overcome the hurdle of low transduction efficiency. The radiosensitive nature of multiple myeloma could be a major contributing factor to the success of radiotherapy in this case, and although NIS may become a new avenue for therapy of this currently incurable cancer, more extensive studies are certainly warranted. More recently, a significant regression of pancreatic carcinoma transduced in vivo with a replication-defective adenoviral construct containing NIS under the MUC1 promoter (Ad-MUC1-NIS) in mice was reported after iv 131 I Ϫ treatment. In this study, no isotope was detected in the liver, in contrast to the hepatotoxicity induced by nonspecific promoters such as CMV (291) . Many studies using tissue-specific promoters have followed.
Another tumor-specific approach not limited to a particular tumor type is the use of tumor-specific promoters to drive expression of a therapeutic transgene into tumor cells. One example is the use of telomerase. Aberrant telomerase gene expression in cancer remains an area of continued interest for development of anticancer therapeutics (310, 311) . Recombinant adenoviruses have been used to introduce NIS into ovarian and pancreatic carcinoma xenografts. Using NIS as a reporter gene, the activities of the telomerase promoters have been monitored by PET with 124 I Ϫ . Most recently, the possibility of using these constructs therapeutically has been investigated. Using the promoters of the 2 subunits of telomerase, the RNA subunit (hTR) and the reverse transcriptase subunit (hTERT), to transcriptionally target NIS in colon and melanoma xenograft models, delayed tumor progression was demonstrated after a 1-mCi therapeutic dose of 131 I Ϫ administered ip (312) . Although most of the work on NIS gene transfer has been done using adenoviral vectors, some effort has been made to use the oncolytic measles virus (MV). Recombinant replication-competent viruses based on the Edmonston strain of MV (MV-Edm) have been shown to be highly effective oncolytic viruses that can potentially be used to treat a broad range of tumors (313) (314) (315) (316) . MV recognizes CD46 on the surface of target cells. Upon infection, it induces syncytium formation and lysis. For replication-competent viruses, it is crucial to monitor the viral distribution, adjust dosing, and assess outcome. Thus, MV-NIS was engineered to retain the oncolytic capacity of the parent virus, allowing noninvasive detection of its distribution and expression with 123 I Ϫ over time. Additionally, an enhancement of the therapeutic effect can be achieved by 131 I Ϫ administration. MV-NIS has been approved by the Recombinant DNA Advisory Committee for a phase I study in patients with advanced or refractory multiple myeloma (317) (318) (319) (320) . After pharmacological and toxicological studies of MV-NIS in mice and squirrel monkeys (316), a clinical trial using iv MV-NIS to treat multiple myeloma with or without cyclophosphamide in patients with recurrent or refractory multiple myeloma is ongoing at the Mayo Clinic at the time of writing. The purpose of administering cyclophosphamide in this trial is to suppress the immune response elicited by MV, because the use of MV-NIS may be hindered by immune clearance. Because children are routinely vaccinated against measles, most of the population has antibodies against it; therefore, iv-administered MV-NIS is rapidly neutralized and cleared by antiviral antibodies. To address this problem experimentally, different modes of viral delivery have been explored. Given their natural bone marrow tropism, myeloma cells themselves were used to carry MV-NIS to sites of disease deposits in mice. By infecting myeloma cells ex vivo and infusing them back into mice with disseminated disease, the authors showed that the antitumor activity of MV-NIS was evident even in previously immunized mice. Thus, the problem of immune clearance could perhaps be circumvented by systemically delivering cells infected with MV-NIS, rather than iv injecting MV-NIS (321) . Whether this can be translated to humans should be investigated, as it may provide a new treatment modality for this disease. Additionally, although MV has been used for its oncolytic properties, highly specific tumor targeting remains a problem. MV recognizes CD46 and signaling lymphocytic activation molecule (SLAM) receptors on target cells (322, 323) . Although the WT virus enters cells more efficiently through SLAM, CD46 is preferentially used by the attenuated MV-Edm strain. CD46 functions to protect tumor cells against complement-mediated lysis and is overexpressed in tumor cells (324) ; these molecules are present in all nucleated primate cells, and so methods to enhance tumor tropism would be extremely desirable. Engineering molecules capable of targeting MV to cancer cells is being actively explored (321, 325) .
In numerous preclinical evaluations of NIS-mediated radiotherapy, the responses observed, although impressive, were not sustained, thus leading to resumption of tumor growth. Given that the overall response to radiotherapy is highly dependent on the vulnerability of the endothelial cells (ECs) (327) and that radiotherapy itself activates angiogenesis (328) , in a thorough study, Schlumberger's group (329) evaluated the tumoricidal effect of NIS-mediated 131 I Ϫ radiotherapy in conjunction with canstatin (with both NIS and castatin delivered through intratumoral Ad virus injection) in the MDA 231 human metastatic breast cancer xenograft model and the transgenic retinal pigmented epithelium spontaneous tumor model. Canstatin is a 24-kDa human basement membrane-derived fragment of human collagen that has been shown to inhibit angiogenesis and tumor growth by inducing EC apoptosis, reducing EC migration and tube formation in mice (330) . It has been shown to bind to the ␣ v ␤ 3 and the ␣ v ␤ 3 -integrin receptors and promote mitochondrial apoptosis in both ECs and tumor cells (330 -332) . Interestingly, contrary to the emphasized role of hypoxia inducible factor-1␣ (HIF-1␣) as a contributing factor to radioresistance, this study showed that it also plays a pivotal role in inducing apoptosis by forcing both the tumor and ECs into aberrant mitoses. This particular combination therapy is able to overcome the prosurvival mechanisms induced by activation of HIF-1␣ in response to radiotherapy, and further highlights the complexity of HIF-1␣ signaling in tumors.
To our knowledge, this is the only time that radioiodide therapy has been combined with an antiangiogenic agent. Magnon et al (329) observed as much as an 86% sustained growth reduction of MDA 231 xenografts and a 70% reduction in the intraocular tumor model after a single dose of 131 I Ϫ during a relatively long follow-up period of 30 days. Furthermore, these authors used a single therapeutic dose of only 300 Ci (as compared with 1-3 mCi administered in most mice and up to 18 mCi in rat studies), making the point that the doses for which a therapeutic effect is seen in xenografts are far too high to be useful in a clinical setting. As alternatives to virus-based delivery systems, several synthetic vectors for efficient systemic delivery of NIS have been developed (333) (334) (335) . The greatest benefit that NISmediated radionuclide therapy could confer would be an enhancement of our ability to treat metastatic disease, as opposed to primary tumors. The last several years have seen some development of non-virus-based methods for systemic delivery of the NIS gene, such as the use of synthetic polyamine vectors with high tumor affinity to deliver CMV-NIS pcDNA3 to neuroblastoma cells, which resulted in a 51-fold increase in ClO 4 Ϫ -sensitive I Ϫ uptake in vitro. After iv administration of NIS-containing polyplexes, 8% to 13% of each injected dose of 123 I Ϫ was accumulated per gram of tissue, as observed by scintigraphy and ex vivo ␥-counting in mouse neuroblastomas, and critically, tumor growth was significantly delayed, and survival improved (334) . A follow-up study used different polyplexes based on linear polyethylamine, polyethylene glycol, and a synthetic peptide GE11 (an epidermal growth factor receptor-specific ligand) to target NIS to tumoral sites in a hepatocellular carcinoma xenograft mouse model. This too resulted in delayed tumor growth and longer survival after radioiodide ablation (333) . Another study by the same group evaluated the potential of biodegradable nanoparticle vectors based on pseudodendritic oligoamines, with similar results (333) . Clearly, synthetic vectors may offer a novel, efficient, and promising approach to NIS gene transfer.
D. Downregulation of thyroid function is required for NIS-mediated 131 I ؊ therapy for extrathyroidal tumors
In using NIS-mediated radioiodide therapy to destroy extrathyroidal tumors, whether they endogenously express NIS (ie, Ͼ80% of breast cancers) or NIS expression is induced via gene transfer, it is important to prevent healthy thyroid cells from taking up administered 131 I Ϫ .
Owing to its ability to organify I Ϫ , the thyroid acts as a sink for the isotope, consequently destroying the gland and limiting the amount of isotope available to NIS-expressing tumors that are incapable of organification. For these reasons, it is key to selectively downregulate NIS expression in the thyroid before initiation of therapy. Our group has shown that thyroidal NIS can be efficiently and selectively downregulated with T 3 in combination with MMI to inhibit organification in humans (201) . T 3 and T 4 negatively regulate TSH production by the adenohypophysis. Given that TSH induces NIS biosynthesis and plasma membrane targeting, a reduction in TSH results in a reduction in NIS expression and thus in I Ϫ accumulation in the thyroid.
TH therapy is not the only way to downregulate NIS. The Wolff-Chaikoff effect and its escape (Section VIII.B.) can be exploited for this purpose as well. High doses of I Ϫ , via the escape from the Wolff-Chaikoff effect (Figure 11 ), will also downregulate NIS expression. High doses of I Ϫ (Lugol's solution) are often administered before thyroid surgery to reduce thyroid gland size, vascularity, and function. Two NIS mutants discussed in Section VI.D. may prove to be particularly useful for NIS-mediated gene therapy, as they display an extremely low affinity for I Ϫ but transport ReO 4 Ϫ . It is unknown whether I Ϫ -mediated NISdownregulation occurs in tumors. If it does, expressing mutant NIS in these tumors, as opposed to WT NIS, would make them less susceptible to NIS downregulation by I Ϫ pretreatment to reduce thyroidal NIS expression while still allowing them to concentrate the therapeutic isotope 188 (338, 339) . 188 Re has a half-life of only 16.7 hours and emits higher-energy ␤-particles than 131 I Ϫ (268). These are effective over a greater range, sufficient to eradicate larger tumors by a crossfire effect, whereas the lower-energy ␥-photons (155 keV) are suitable for imaging (268, 340) . It has been estimated that the number of atoms of radioisotope per gram tumor needed to produce a cure probability of 90% at the optimal range is 12-fold higher for 131 extrathyroidal malignancy would require that his/her thyroid be protected from the radioisotope. As indicated in the previous section, one way to accomplish this objective is to downregulate NIS expression by administering T 4 (201) . T 4 must be administered for 1 week before the onset of therapy, as a result of the long half-life of NIS. Although this approach is effective, it has a negative effect on the patient's well-being, and patients may not comply. In addition, this treatment is not suitable for patients with heart conditions. One potential way to overcome these hurdles would be to express G93E 
I
F. Additional considerations pertaining to NIS gene transfer
The extremely high dose of radioisotope administered in some preclinical studies will likely not be translatable to humans. Thus, it may not be possible to achieve the effective lethal dose per body weight equivalent. Treatment regimens described in mice range from 500 Ci to 3 mCi and up to 18 mCi in rats (262) . Therefore, it seems crucial to validate that lower doses of radioiodide would still produce a therapeutic effect.
Although there exist concerns that the lack of iodide organification in extrathyroidal tissues would limit retention of radioiodide and thus produce no therapeutic benefit, it is clear from results in the literature that NISmediated radioiodide treatment is effective in the absence of organification (267, 270, 307, 308) and thus could be useful in extrathyroidal tumors.
Although most studies focus on reduction in tumor volume or delay in tumor growth as a readout of the effectiveness of treatment, this alone may not be an accurate portrayal of human disease. Therapeutic efficacy is not illustrated by tumor volume alone, particularly on the short time scale that murine tumor studies are conducted. Thus, it would be useful to not only examine the size, weight, and volume of the tumor mass but also combine it with analysis of various markers of proliferation, apoptosis, and even angiogenesis. Although the obstacle to cancer therapy remains metastatic disease rather than elimination of the primary tumor in most cases, introduction of viral vectors should focus on systemic delivery rather than direct intratumoral injection.
X. Concluding Remarks
The relatively young field of NIS research at the molecular level, born with the cloning of the protein in 1996, seems to be reaching a certain maturity, and doing so by delivering a healthy dose of surprises and novel potential applications. Previous reviews of NIS research accurately predicted that the study of NIS would lead to new insights into the structure/function of plasma membrane proteins and into the mechanisms of NIS activity and of the differential regulation of NIS in different tissues, and it has. The exciting and highly promising search for ways of extending the benefits of NIS-mediated radioiodide treatment of thyroid cancer to other malignancies has continued with considerable success, and some of the latter studies have reached the stage of clinical trials. Still, no one could have foreseen that NIS would be found to transport different anion substrates with different stoichiometries, that amino acid substitutions at a single position in NIS would suffice to switch the transport of some anion substrates from electroneutral to electrogenic (and back), that NIS molecules would be engineered to selectively transport only a desired anion and thus optimized for gene transfer, or that NIS would be shown to be regulated in the thyroid by a K ϩ channel. It would have been difficult to anticipate that NIS would be demonstrated to actively translocate ClO 4 Ϫ , thus thrusting NIS to the center of the debate on the public health effects of ClO 4 Ϫ contamination of food and water. The recent x-ray resolution of the structures of the bacterial transporters LeuT, vSGLT, Mhp1, and BetP; the new notion that proteins without sequence homology between them may nevertheless share a similar fold; and the generation of a new homology model for NIS have all had a strong impact on the continued elucidation of structure/ function information on the symporter.
To conclude, the future of basic NIS research, in addition to continuing the trends discussed in this review, will also ultimately aim at the determination of the protein's 3-dimensional crystal structure, a feat that has yet to be achieved for any mammalian symporter. On the other hand, given the unique properties of NIS as an easily monitored therapeutic and reporter molecule, its clinical applications in the diagnosis and treatment of extrathyroidal cancers, and possibly other medical conditions, can only be expected to grow in number and scope.
